MedTrace Logo

The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .

NCT07247656 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-11-25

No results posted yet for this study

Summary

The goal of this clinical trial is - Comparison of Empagliflozin - Linagliptin with Empagliflozin - Metformin combination therapy in reduction of body weight in T2DM Patients and it included 200 diabetic subjects with total study period of 12 weeks and individual study period of 4 weeks .

Conditions

  • Diabete Mellitus

Interventions

DRUG

(Empagliflozin 10 mg+ Tab Linagliptin 5mg)

(Empagliflozin 10 mg+ Tab Linagliptin 5mg)was given once Orally daily

DRUG

Tab Empagliflozin 10 mg + Tab Metformin 500 mg

Tab Empagliflozin 10 mg once daily, along with combination of Tab Metformin 500 mg

Sponsors & Collaborators

  • Bahria University

    lead OTHER

Principal Investigators

  • NABILA RAFI · DOCTOR

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2023-03-01
Completion
2023-05-01

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07247656 on ClinicalTrials.gov